Document is current
Any future updates will be listed below
-
Authors
Yosipovitch, Gil
Borkowska, Katarzyna
Frampton, James
Schaible, Kassandra
Betts, Marissa
Jack, Katrin
Jabbar Lopez, Zarif
Neupane, Binod
Piketty, Christophe
Subramanian, Ramkumar
Fernández de Trocóniz, Jorge Puelles
-
Funding
Funding for this research was provided by:
Galderma
- License Information
-
More Information
Article History
Received: 22 April 2026
Accepted: 4 June 2026
First Online: 25 June 2026
Declarations
Conflict of Interest: Gil Yosipovitch is a consultant and a board member of Abbvie, Arcutis, Almiral, Amgen, Celldex, Escient Health, Eli Lilly, Galderma, GSK, Kiniksa, LEO Pharma, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Vifor, and Pfizer. Gil Yosipovitch is an Editorial Board member of Dermatology and Therapy . Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Katarzyna Borkowska, James Frampton, Kassandra Schaible, Marissa Betts, and Binod Neupane are employees of PPD Evidera, the clinical research business of Thermo Fisher Scientific, which received funding from Galderma in connection with the development of this manuscript and research. Katrin Jack, Zarif Jabbar Lopez, Christophe Piketty, Ramkumar Subramanian, and Jorge Puelles Fernández de Trocóniz are employees of Galderma and hold company stock.
